Related Experiment Video

Updated: Oct 19, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Clinical trials in Alzheimer disease: debate on the use of placebo controls

C H Kawas1, C M Clark, M R Farlow

  • 1Department of Neurology and Alzheimer's Disease Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.

Alzheimer Disease and Associated Disorders
|September 15, 1999
PubMed

Insights

The ethical debate surrounding placebo-controlled trials for Alzheimer disease (AD) treatments is ongoing. Careful consideration of ethical issues is crucial when designing AD clinical trials, especially as new therapies emerge.

Area of Science:

  • Neuroscience
  • Medical Ethics
  • Clinical Pharmacology

Background:

  • Growing public concern and pharmaceutical investment in Alzheimer disease (AD) research have intensified the need for effective treatments.
  • The availability of FDA-approved therapies has brought the ethical debate on placebo-controlled trials in AD research to the forefront in the US.

Purpose of the Study:

  • To explore the ethical considerations of using placebo-controlled trials in Alzheimer disease (AD) research.
  • To present contrasting viewpoints on placebo use in AD clinical trials without making definitive recommendations.

Main Methods:

  • Review of current ethical debates and arguments regarding placebo-controlled trials in AD research.
  • Analysis of how scientific and practical goals of clinical trials influence ethical priorities.

Main Results:

  • Arguments for and against placebo-controlled trials in AD research are significant but do not offer a clear consensus for universal application.
  • The ethical priorities of clinical trials are inherently affected by their specific scientific and practical objectives.

Conclusions:

  • Placebo-controlled trials in AD research should be designed with careful attention to ethical issues.
  • The ethical framework for placebo use in AD studies requires ongoing re-evaluation as new treatments become available.
  • Informed decision-making necessitates the inclusion of patients, caregivers, physicians, and ethicists in the discussion on placebo use.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...